Trademark Overview
On Friday, July 19, 2024, a trademark application was filed for ABILEAP with the United States Patent and Trademark Office. The USPTO has given the ABILEAP trademark a serial number of 98657918. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, July 1, 2025. This trademark is owned by ABILITY BIOLOGICS INC. The ABILEAP trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Antibody products and molecules, namely, antibodies acting as immune modulators for medical purposes; colostral antibodies for medical purposes; pharmaceutical antibodies for medical use in the treatment of hereditary angioedema (HAE); pharmaceutical antibodies for medical use in the treatment of respiratory diseases and respiratory syndromes; pharmaceutical antibody preparations for the treatment of auto-immune diseases; pharmaceutical antibody preparations for the prevention and treatment of auto-immune diseases; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; antibody products, namely, antibody reagents use...
Antibody products and molecules, namely, antibody reagents used for the detection of antigens in cells and tissue for scientific purposes; antibody products and molecules, namely, antibodies acting as immune modulators for scientific purposes
Antibody profiling for scientific research purposes and for discovery and development of new biotherapeutics; providing an online scientific database and website featuring information about medical and scientific research in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; molecule development, namely, pharmaceutical drug development services; scientific research in the field of conducting clinical trials for others; providing temporary use of a non-downloadable software for managing information in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; Platform as a service (PAAS) featuring a computer software platform for analyzing molecular and clinical data to develop antibodies against immune targets; chemical analysis in the field of molecular biology; biotherapeutic research services, namely, molecular analysis and product optimization for the purpose of pharmaceutical development
